{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:51Z","timestamp":1778056551473,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.thromres.2019.10.006","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T01:53:33Z","timestamp":1571795613000},"page":"119-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-1508","authenticated-orcid":false,"given":"Akinori","family":"Sairaku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Onohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Hironobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuki","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2019.10.006_bb0005","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.","DOI":"10.1056\/NEJMoa0905561"},{"key":"10.1016\/j.thromres.2019.10.006_bb0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.10.006_bb0015","doi-asserted-by":"crossref","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.","DOI":"10.1056\/NEJMoa1107039"},{"key":"10.1016\/j.thromres.2019.10.006_bb0020","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.10.006_bb0025","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.thromres.2019.10.006_bb0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.10.006_bb0035","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.thromres.2019.10.006_bb0040","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"Heidb\u00fcchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.thromres.2019.10.006_bb0045","first-page":"632","article-title":"Tajiri M","volume":"77","author":"Hori","year":"2013","journal-title":"J-ROCKET AF Study Investigators. Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients with Non-Valvular Atrial Fibrillation: Subanalysis of J-ROCKET AF for Patients with Moderate Renal Impairment. Circ J."},{"key":"10.1016\/j.thromres.2019.10.006_bb0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.acvd.2013.04.009","volume":"106","author":"Pernod","year":"2013","journal-title":"Arch Cardiovasc Dis."},{"key":"10.1016\/j.thromres.2019.10.006_bb0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2019.10.006_bb0060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/pace.13293","article-title":"Head-to-head comparison of acute and chronic pulmonary vein stenosis for cryoballoon versus radiofrequency ablation","volume":"41","author":"Watanabe","year":"2018","journal-title":"Pacing Clin Electrophysiol."},{"key":"10.1016\/j.thromres.2019.10.006_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10557-015-6632-3","article-title":"Stroke prevention in atrial fibrillation: a clinical perspective on trials of the novel oral anticoagulants","volume":"30","author":"Morais","year":"2016","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.thromres.2019.10.006_bb0070","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","article-title":"Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study","volume":"38","author":"Godier","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.thromres.2019.10.006_bb0075","article-title":"A level-headed approach to measuring direct oral anticoagulants: a 2-year retrospective analysis of DOAC levels from a tertiary UK centre","author":"Denny","year":"2018","journal-title":"Int J Lab Hematol."},{"key":"10.1016\/j.thromres.2019.10.006_bb0080","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.athoracsur.2017.11.066","article-title":"Bleeding complications after use of novel oral anticoagulants in patients undergoing cardiac surgery","volume":"105","author":"Hassan","year":"2018","journal-title":"Ann Thorac Surg."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819304475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819304475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:40:04Z","timestamp":1758735604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819304475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":16,"alternative-id":["S0049384819304475"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.10.006","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}